• Publications
    Expected Returns Articles
  • Research
    Companies Funds Top 40 My Studies
  • Stock Screen
    New Stock Screen Manage Screens
  • Dashboards
    My Dashboards New Dashboard
  • Forum
  • Events
  • Search
  • Contact Us
  • Sign In

Commence Sharing of Actionable Ideas

Stock Screen, by Mark Robertson, Managing Partner November 1st, 2019


During the month of October, we carefully search for small company ideas for the next year’s Best Small Companies list.

At Manifest Investing, we are co-sponsors and producers of our monthly webcasts known as the Investing Round Table. The agenda usually includes a review of screening results by one or more of the participants in our quest for actionable ideas to study. During the October 2019 Round Table, the emphasis and focus was on faster-growing companies with excellent quality characteristics.

During the month of October, we carefully search for small company ideas for the next year’s Best Small Companies list. The hunt is for smaller, faster-growing companies that rank among the upper percentiles of quality companies that exhibit double-digit growth rate forecasts. The primary screening criteria are:

(1) Quality Rank > 60 (Excellent & Good Companies)
(2) Growth Forecast > 10%

This is combined with our traditional parade of opinions that range from oversold technical factors, to stock prices near 52-week lows, to superior return forecasts and attractive price-to-fair value ratios and a dash of expectations for the year ahead.

We’ve circled the best and highest ranked conditions among the parade of characteristics and opinion shown in the accompanying figure.

The Round Table audience selected BioSpecifics Technologies (BSTC) as a promising company in the realm of reducing collagen that happens to garner the most circles as shown in the accompanying chart. Caveat emptor as this selection (BSTC) is a very small company with $36 million in trailing 12-month sales. Forrester Research (FORR) has been a community favorite in the past and merits current consideration. Pacira Pharma (PCRX) is focused on driving improved patient outcomes with opioid-reducing strategies. That seems necessary and timely … we’ll hope for success in their endeavors.

Manifest Investing: Median Return Forecast. The storm that was December or 4th Quarter 2018 has given way to a return to new highs and a median projected annual return (PAR) of 9.0%, closer to historical norms.

Mark Robertson

Mark Robertson is founder and managing partner of Manifest Investing, a source for research and portfolio management focusing on strategic long term investors.

Expected Returns, Nov 2019
  • BioSpecifics Technologies (BSTC)
  • Commence Sharing of Actionable Ideas
  • Tin Cup Demonstration Portfolio (November 2019)
Forrester Research (FORR)
Quality 46
PAR 8.6%
Pacira Pharma* (PCRX)
Quality 41
PAR 11.1%
Join Manifest Investing

Manifest is an easy to use resource for your investing.

Create dashboards, research companies, discuss your ideas on the forum, and get insight into long-term investing.


Learn More Get Started

© 2006 - 2025 Manifest Investing. All rights reserved.
About | Terms of Service | Disclaimer | Privacy Policy

Legend
Quality Legend:
Blue Excellent with quality greater than 80.
Green Good with quality between 60 and 80.
Neutral Average or below average with quality between 20 and 60.
Red Poor with quality less than 20.
Companies with less than 10 years of history are penalized by 5 points per year.
PAR Legend:
Green PAR is within the target range of MIPAR +5-10%, currently 5.1%-10.1%
Yellow PAR is above the target range of MIPAR +10%, currently 10.1%
PAR Projected Annual Return
MIPAR The Manifest Investing Median PAR of all stocks in the database.
Company Name Legend:
* Not covered by Value Line Standard Edition.
b Uses price-to-book value for valuation purposes.
P/CF Uses price-to-cash flow for valuation.